RAF Kinase Inhibitors Targeting Activation Loop Pockets
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule kinase inhibitors for treating proliferative diseases like cancer and rheumatoid arthritis are limited in their ability to effectively target and modulate RAF kinases, particularly due to challenges in binding to specific activation/deactivation mechanisms and conformational changes in kinase proteins.
Innovation Solution
Development of novel kinase inhibitor compounds that target RAF kinases and other kinases in the RAS-RAF-MEK-ERK-MAP kinase pathway, specifically designed to bind to unique pockets and modulate kinase activity through various chemical moieties and conformations, thereby inhibiting abnormal signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current small molecule kinase inhibitors are used to treat proliferative diseases, then they can bind to ATP binding domain or DFG-in-conformation pocket, but they fail to effectively target RAF kinases activation/deactivation mechanisms
Solution Approach 1:
The patent segments the kinase binding site into multiple distinct pockets: the ATP binding domain, the DFG-in-conformation pocket, and the activation loop pocket. By designing compounds that can selectively target these segmented regions, particularly the previously inaccessible activation loop pocket, the invention achieves reliable RAF kinase inhibition while maintaining versatility in binding modes.
Solution Approach 2:
The patent introduces a new dimensional approach by targeting the activation loop pocket, which represents a previously unexplored binding dimension in RAF kinase inhibition. This additional binding dimension allows compounds to modulate kinase activity through mechanisms beyond traditional ATP competition, thereby improving effectiveness against RAF kinases while expanding binding versatility.
2Reliability
If inhibitors bind to ATP binding domain to compete with ATP, then they can inhibit kinase activity, but they cannot effectively address conformational changes in kinase proteins
Solution Approach 1:
The patent employs dynamic binding strategies by designing compounds that can adapt to different kinase conformations. The inhibitors are structured to bind not only to the static ATP pocket but also to dynamic regions like the activation loop and DFG motif, allowing them to effectively inhibit kinase activity across various conformational states rather than being limited to a single rigid binding mode.
3Reliability
If dominant mutation at position 600 in BRAF kinase substitutes glutamic acid for valine, then BRAF becomes constitutively active, but current inhibitors cannot effectively target this mutated form
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features tailored to interact with the mutated BRAF conformation. The inhibitors incorporate molecular moieties that can recognize and bind to the altered activation loop structure resulting from the V600E mutation, thereby achieving reliable inhibition of constitutively active mutated BRAF while maintaining the ability to adapt to different mutation types.
Data Source
AI summary
The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.